1. THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY. (2nd June 2020) Authors: Lafyatis, R.; Spiera, R.; Domsic, R.; Papazoglou, A.; Ligon, C.; Zinger Morse, C. M.; Denis, J. F.; Davis, M.; Gruosso, T.; Tremblay, G.; O'connor Mccourt, M.; Sinclair, S.; Delara, J.; Alvarado, K.; Wood, D.; Nadler, P.; Volkmann, E. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 394 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗